Can surgery buy more time for ovarian cancer patients?

NCT ID NCT07295132

Not yet recruiting Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a second surgery to remove visible tumors (secondary cytoreductive surgery) after chemotherapy helps women with platinum-sensitive recurrent ovarian cancer. About 160 participants will be randomly assigned to get surgery plus chemo or chemo alone. The goal is to see if surgery delays the cancer from growing back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secondary cytoreductive surgery (surgery to remove visible tumor) and platinum-based chemotherapy
What this could lead to: If successful, this could show that adding surgery after chemotherapy helps women with recurrent ovarian cancer live longer without their cancer getting worse.
What could go wrong: This is a Phase 2 trial with only 160 participants, so results are preliminary. Surgery carries risks like infection or complications, and it may not improve survival for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.